The first presentation, "Psychedelics: Promise, Peril, and Health Equity in African Americans," examines one of the most important questions facing psychiatry today: As new psychiatric treatments emerge, will all communities have equitable access to them
The same week those letters went out, A major telehealth platform announced a partnership with a brand-name GLP-1 manufacturer in early 2026, agreeing to shift toward branded medications and pull back most compounded GLP-1 advertising
However, the interpretation of these outcomes is complex, as they involve the confounding effects of drug combination, extended follow-up, and changes in conception-related behaviors
Combining GLP-1 receptor agonists with DPP-4 inhibitors is generally not recommended due to limited additive benefit
Individuals were excluded if they met any of the following criteria: chronic liver disease other than NAFLD, including alcohol, viral, drug-induced, autoimmune and genetic diseases, liver cirrhosis, or clinical diagnosis of hepatic decompensation (such as oesophageal varices or ascites)
A GLP-1 weight loss program review should answer more than one question: Will I lose weight? The better question is whether the program gives you safe prescribing, realistic expectations, consistent follow-up, and a plan you can continue after the first few months
